Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(20%)

Results Posted

50%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

60%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

1(20.0%)

Phase 2Efficacy & side effects

3(60.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

Terminated1

unknown1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (20.0%)

Phase 23 (60.0%)

Phase 31 (20.0%)

Trials by Status

terminated120%

completed240%

unknown120%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

recruitingphase_2

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

NCT02483884

Clinical Trials (5)

Showing 5 of 5 trials

NCT06484361Phase 2

PET/MRI to Stage Prostate Cancer Patients

Recruiting

NCT05806853Phase 2

PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric Study

Completed

NCT02624518Phase 2

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

Completed

NCT03731026Phase 3

The LightPath® and 68Ga-RM2 in Breast Cancer Study

Unknown

NCT02483884Phase 1

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Terminated

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5